Study
Resveratrol for Improved Performance in the Elderly (RIPE) — clinical trial listing
A rare two-year cognitive-and-physical outcome trial comparing 300 mg and 1,000 mg per day of resveratrol against placebo in older adults.
Summary Does resveratrol improve thinking and physical ability in older adults? Show / hide ↓
Researchers planned a two-year study in older adults, assigning people by chance to take 300 milligrams of resveratrol daily, 1,000 milligrams daily, or a placebo, an inactive look-alike treatment. They planned to measure thinking skills and physical performance. The trial listing does not provide usable results or show whether resveratrol helped. No full results paper has been published publicly.
What this means for you: This study gives you no reason to buy resveratrol for better thinking or physical ability. The question is worthwhile, but it remains unanswered because the results are not available.
weak evidenceRIPE is one of the longer-duration resveratrol trials on record. It compares 300 mg per day and 1,000 mg per day against placebo for 24 months, with cognitive and physical performance as primary endpoints, in older adults. We include the ClinicalTrials.gov listing because the full outcome paper has been slow to publish. This is exactly the kind of long-duration, dose-comparison, hard-endpoint trial that could actually settle whether resveratrol does anything meaningful in an aging population. It has not yet done so publicly.
Study status and outcomes are documented at ClinicalTrials.gov identifier NCT01126229.
Results have not yet been published in a peer-reviewed journal in a form that lets us judge effect size.
Cited by
1 encyclopedia entries reference this study.